BioNTech SE (NASDAQ:BNTX) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lowered its stake in shares of BioNTech SE (NASDAQ:BNTX) by 8.8% during the fourth quarter, Holdings Channel reports. The fund owned 43,956 shares of the company’s stock after selling 4,228 shares during the period. Pictet Asset Management Holding SA’s holdings in BioNTech were worth $5,009,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of BNTX. Charles Schwab Investment Management Inc. increased its holdings in BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock worth $15,919,000 after purchasing an additional 74,119 shares during the period. SG Americas Securities LLC increased its stake in shares of BioNTech by 412.3% during the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after buying an additional 33,375 shares during the period. Mirabaud & Cie SA acquired a new stake in BioNTech in the fourth quarter valued at approximately $684,000. Redmile Group LLC acquired a new stake in BioNTech in the third quarter valued at approximately $18,345,000. Finally, Vestcor Inc purchased a new position in BioNTech in the third quarter worth approximately $784,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Price Performance

Shares of BNTX opened at $92.01 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm has a 50-day simple moving average of $109.42 and a 200-day simple moving average of $113.12. The company has a market capitalization of $22.08 billion, a price-to-earnings ratio of -43.81 and a beta of 0.30.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period last year, the firm earned $1.90 EPS. On average, equities research analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BNTX shares. Wells Fargo & Company assumed coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective on the stock. Morgan Stanley cut their price target on BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 11th. BMO Capital Markets upped their price objective on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Truist Financial assumed coverage on BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 target price for the company. Finally, HC Wainwright lowered their price target on BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.44.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.